Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 54.65M | 51.29M | 39.30M | 22.47M | 13.04M | 6.05M |
Gross Profit | 45.93M | 42.96M | 33.04M | 17.47M | 9.40M | 4.61M |
EBITDA | -46.15M | -54.89M | -38.73M | -40.74M | -40.60M | -11.48M |
Net Income | -52.25M | -59.97M | -41.20M | -41.43M | -43.08M | -14.11M |
Balance Sheet | ||||||
Total Assets | 119.56M | 133.41M | 115.23M | 124.94M | 152.55M | 64.78M |
Cash, Cash Equivalents and Short-Term Investments | 95.03M | 105.93M | 90.57M | 106.19M | 142.07M | 59.11M |
Total Debt | 50.54M | 50.43M | 30.61M | 7.09M | 0.00 | 19.28M |
Total Liabilities | 61.63M | 62.36M | 39.28M | 15.76M | 6.59M | 358.01M |
Stockholders Equity | 57.93M | 71.06M | 75.95M | 109.18M | 145.96M | -293.24M |
Cash Flow | ||||||
Free Cash Flow | -39.43M | -40.51M | -39.61M | -43.36M | -28.91M | -16.41M |
Operating Cash Flow | -39.12M | -39.14M | -39.02M | -42.68M | -27.73M | -16.10M |
Investing Cash Flow | -306.00K | -1.36M | -591.00K | -685.00K | -1.18M | -311.00K |
Financing Cash Flow | 64.04M | 55.87M | 23.98M | 7.49M | 111.88M | 49.78M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | 289.32M | 51.38 | 4.69% | ― | 27.22% | 695.07% | |
60 Neutral | 272.81M | -3.53 | -12.39% | ― | 14.65% | -86.36% | |
48 Neutral | $196.92M | ― | -92.33% | ― | 23.11% | 18.06% | |
48 Neutral | 241.36M | -4.11 | 128.34% | ― | 45.50% | 53.07% | |
44 Neutral | 39.31M | -4.58 | -25.02% | ― | 93.07% | 13.25% | |
41 Neutral | 144.89M | -2.88 | 532.08% | ― | 29.34% | -283.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 4, 2025, CVRx announced the appointment of Brent Binkowski as Chief Operating Officer, effective August 11, 2025. Binkowski brings over 20 years of experience in medical devices, which is expected to enhance CVRx’s operations. The company reported a 15% increase in total revenue for the second quarter of 2025, reaching $13.6 million, driven by growth in the U.S. heart failure market. The number of active implanting centers in the U.S. grew by 27% since June 2024. CVRx is also benefiting from favorable CMS proposals for Barostim reimbursement, positioning the company for continued growth.
The most recent analyst rating on (CVRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.